CommercialCoverageMedium impact
08.00.08k, Radioimmunotherapy with Ibritumomab Tiuxetan (Zevalin®) (Independence Administrators)
Independence Blue Cross·Oncology, Hematology, Nuclear Medicine·Medical Policy
Effective date
May 30, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has archived a medical policy regarding radioimmunotherapy with Ibritumomab Tiuxetan (Zevalin®). This appears to be an administrative action removing an existing policy from active status, which may indicate the treatment is no longer covered or the policy has been consolidated elsewhere.
Action Required
By June 15, 2025: Billing team must verify current coverage status for Ibritumomab Tiuxetan (Zevalin®) radioimmunotherapy with Independence Administrators before submitting any related claims. Contact payer directly to confirm if coverage has been transferred to a different policy or if the treatment is no longer covered. Update billing system notes accordingly to prevent claim denials.